Panelists discuss how personalizing tardive dyskinesia treatment involves a patient-centered approach that balances symptom impact, medication optimization, and comorbid psychiatric management—utilizing VMAT2 inhibitors alongside careful monitoring and collaboration among clinicians and pharmacists to tailor dosing and improve quality of life.